Telmisartan

( DrugBank: Telmisartan / KEGG DRUG: Telmisartan )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
57Idiopathic dilated cardiomyopathy1
66IgA nephropathy4
IDDisease name (Link within this page)Number of trials
67Polycystic kidney disease2
222Primary nephrotic syndrome1

6. Parkinson disease


Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

57. Idiopathic dilated cardiomyopathy


Clinical trials : 148 / Drugs : 217 - (DrugBank : 60) / Drug target genes : 46 - Drug target pathways : 143 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 407 / Drugs : 342 - (DrugBank : 73) / Drug target genes : 40 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

67. Polycystic kidney disease


Clinical trials : 251 / Drugs : 278 - (DrugBank : 69) / Drug target genes : 97 - Drug target pathways : 182 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries